Efficacy and safety of γδT cell-based tumor immunotherapy: a meta-analysis.

S. Buccheri, G. Guggino, N. Caccamo, P. Li Donni, F. Dieli

Research output: Contribution to journalArticlepeer-review


Vγ9Vδ2 T cells are important effector cells that may play a role in the anti-tumor immune response. Their capability to exert MHC-nonrestricted lytic activity against different tumor cells in vitro and their detection among tumor infiltrating lymphocytes in a variety of human cancers have supported the development of Vγ9Vδ2 T cell-based immunotherapy in the context of novel treatment against cancer. Accordingly, promising reports from recent clinical trials support the use of V γ9Vδ2 T cells as immunotherapeutic agents, either via adoptive transfer of ex-vivo expanded V γ9Vδ2 T cells or in vivo activation of V γ9Vδ2 T cells with compounds such as phosphoantigens or aminobisphosphonates. In this study we have performed a meta-analysis to assess the objective efficacy and safety of V γ9Vδ2 T cell-based immunotherapy. Database including Pubmed, Web of Science and SCOPUS were investigated to identify relevant studies. Thirteen clinical trials involving patients with advanced or metastatic cancer were selected. In order to estimate the strength of association between V γ9Vδ2 T cell-based immunotherapy and favorable clinical effect or toxicity grade we used event rate (ER) with 95 percent confidence interval (CI). The total effective rate provided significant results (ER = 0.407; P

Original languageEnglish
Pages (from-to)81-90
Number of pages10
JournalJournal of Biological Regulators and Homeostatic Agents
Issue number1
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Cancer Research
  • Immunology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Immunology and Allergy


Dive into the research topics of 'Efficacy and safety of γδT cell-based tumor immunotherapy: a meta-analysis.'. Together they form a unique fingerprint.

Cite this